Viking Therapeutics SG&A Expenses 2014-2024 | VKTX
- Viking Therapeutics annual sg&a expenses for 2023 were $0.037B, a 129.64% increase from 2022.
- Viking Therapeutics annual sg&a expenses for 2022 were $0.016B, a 50.65% increase from 2021.
- Viking Therapeutics annual sg&a expenses for 2021 were $0.011B, a 0.28% decline from 2020.